Immunotherapy for EBV-associated malignancies

Since 1995 to date, more than 250 patients with EBV-related diseases received virus-specific CTL. Cell therapy proved to be safe and effective, and achieved some complete remissions also in patients who failed all previous standard treatments. The first clinical results with EBV-specific CTL were ob...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2011-03, Vol.93 (3), p.281-293
Main Authors: Merlo, Anna, Turrini, Riccardo, Dolcetti, Riccardo, Zanovello, Paola, Rosato, Antonio
Format: Article
Language:English
Subjects:
Adoptive Transfer
Carcinoma
Chronic infection
Clinical trials
Clinical Trials as Topic
Cytotoxicity
Epstein-Barr Virus Infections - immunology
Epstein-Barr Virus Infections - therapy
Hematology
Herpesvirus 4, Human
Hodgkin Disease - immunology
Hodgkin Disease - therapy
Hodgkin Disease - virology
Hodgkin's disease
Humans
Immunoproliferative diseases
Immunotherapy
Lymphocytes T
Malignancy
Medicine
Medicine & Public Health
Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms - immunology
Nasopharyngeal Neoplasms - therapy
Nasopharyngeal Neoplasms - virology
Oncology
Progress in Hematology
Prophylaxis
Remission
Reviews
T-Lymphocytes, Cytotoxic - immunology
T-Lymphocytes, Cytotoxic - transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since 1995 to date, more than 250 patients with EBV-related diseases received virus-specific CTL. Cell therapy proved to be safe and effective, and achieved some complete remissions also in patients who failed all previous standard treatments. The first clinical results with EBV-specific CTL were obtained for both prophylaxis and treatment of post-transplant lymphoproliferative disease arising in stem cell transplant or solid organ transplant recipients. Based on such encouraging results, the same approach was then extended to other EBV-related diseases, namely Hodgkin’s lymphoma, nasopharyngeal carcinoma, and chronic active infection. Nowadays, the modification of the CTL generation protocols and the introduction of new specificities into EBV-specific CTL lines by chimeric antigen receptor transfer allow targeting other viral infections and also non-EBV related malignancies. Aim of this review is to summarize clinical results obtained thus far in adoptive cell therapy approaches with EBV-specific CTL. Moreover, by analyzing ongoing clinical trials, we also provide some insights on the potential future of a successful and paradigmatic history.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-011-0782-2